
Editor’s note: At the time of recording, Alan Bash was serving as Interim CEO of Legend Biotech. He has since resumed his role as President of CARVYKTI® following the appointment of Ingrid Zhang as CEO.In this episode of The BioHub by Avetix, I’m joined by Alan Bash, President of CARVYKTI® at Legend Biotech.Alan shares what drew him to Legend, what he believes has made the company such a standout success in cell therapy, and his experience stepping into the Interim CEO role during an important period of transition.We also discuss the journey behind CARVYKTI, the importance of global partnerships, the challenges of manufacturing and scaling cell therapy, and what the next chapter could look like for Legend as it builds beyond its first major commercial success.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode 238 - Mandana Honu Fathom Therapeutics

Episode 237 - Marc Hedrick & Russell Bradley- Cerenome

Episode 236 - Dan O’Connell - President & CEO of Acumen Pharmaceuticals

Episode 235 - Paul Hastings - CEO NKarta
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.